CNTF and amyotrophic lateral sclerosis: Axokine, the recombinant human variant of CNTF, initially entered human clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) but was repurposed to treat obesity and type 2 diabetes when treated patients were observed to lose body weight.